The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients:a cross-sectional study

Figures & data

Table 1. Clinical and demographic features of the patients stratified by symptom score.

	Symptom category
	Mild–moderate (n = 186)	Severe (n = 214)	p Value
Age (years)	64.08 ± 8.05	65.35 ± 8.48	.404
Height (cm)	171.96 ± 5.79	170.11 ± 5.69	.001*
Weight (kg)	76.66 ± 10.48	78.84 ± 12.15	.061
BMI (kg/m^2)	25.89 ± 3.12	27.23 ± 3.95	.0001*
FBS (mg/dl)	87.32 ± 11.83	90.75 ± 11.56	.001*
Triglyceride (mg/dl)	108.25 ± 37.21	110.32 ± 44.28	.594
TC (mg/dl)	194.35 ± 37.64	196.58 ± 38.18	.128
LDL-C (mg/dl)	134.50 ± 32.14	136.48 ± 32.68	.096
HDL-C (mg/dl)	38.97 ± 6.88	38.59 ± 6.74	.185
TG/HDL ratio	2.91 ± 1.29	2.98 ± 1.31	.464
Waist circumference (cm)	96.60 ± 10.04	98.30 ± 12.48	.116
IPSS	15.53 ± 2.21	21.00 ± 2.04	–
Peak flow rate	8.52 ± 4.25	6.96 ± 2.66	.0001*
Post void residue (ml)	49.29 ± 47.04	82.98 ± 67.96	.0001*
PSA (ng/ml)	2.59 ± 2.10	3.14 ± 2.01	.0001*
Prostate volume (ml)	42.91 ± 17.43	54.78 ± 27.52	.0001*

BMI: body mass index; FBS: fasting blood sugar; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG/HDL: triglyceride/high-density lipoprotein cholesterol; IPSS: International Prostate Symptom Score; PSA: prostate specific antigen.

* Statistically significant at p < .05.

Table 2. Clinical and demographic features of the patients stratified by prostate volume.

	Prostate volume category
	PV <40 ml (n = 204)	PV >40 ml (196)	p Value
Age (years)	62.14 ± 7.69	67.26 ± 7.97	.0001
Height (cm)	169.89 ± 5.94	172.07 ± 5.47	.0001*
Weight (kg)	74.52 ± 11.12	81.04 ± 10.84	.0001*
BMI (kg/m^2)	25.79 ± 3.46	27.39 ± 3.67	.0001*
FBS (mg/dl)	87.09 ± 12.70	91.13 ± 10.50	.0001*
Triglyceride (mg/dl)	101.49 ± 32.54	116.66 ± 46.93	.0001*
TC (mg/dl)	192.68 ± 38.62	193.58 ± 38.88	.125
LDL-C (mg/dl)	133.42 ± 31.24	132.74 ± 32.18	.218
HDL-C (mg/dl)	39.53 ± 6.94	38.01 ± 6.62	.018*
TG/HDL ratio	2.70 ± 1.16	3.18 ± 1.38	.0001*
Waist circumference	95.13 ± 9.80	99.88 ± 12.52	.0001*
IPSS	17.85 ± 3.15	19.23 ± 3.49	.0001*
Peak flow rate	8.41 ± 4.12	6.84 ± 2.60	.0001*
Post void residue	45.80 ± 39.33	89.94 ± 71.43	.0001*
PSA	1.82 ± 1.00	3.77 ± 2.27	.0001*

BMI: body mass index; FBS: fasting blood sugar; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG/HDL: triglyceride/high-density lipoprotein cholesterol; IPSS: International Prostate Symptom Score; PSA: prostate specific antigen.

* Statistically significant at p < .05.

Table 3. Univariate and multivariate analyses of the factors effective on prostate volume.

	Univariate analysis				Multivariate analysis
			95%CI				95%CI
	p	OR	Lower	Upper	p	OR	Lower	Upper
Age	.00001*	1.086	1.056	1.117	.00001*	1.125	1.088	1.164
BMI	.00001*	1.135	1.070	1.204	.003*	1.119	1.040	1.204
WC	.00001*	1.038	1.019	1.058	.623	1.011	0.969	1.054
FBS	.001*	1.031	1.013	1.050	.275	1.013	0.990	1.035
TG	.00001*	1.010	1.004	1.016	.002*	1.043	1.016	1.071
TC	.078	0.918	0.869	0.956	–	–	–	–
LDL-C	.464	0.992	0.961	1.010	–	–	–	–
HDL-C	.028*	0.967	0.939	0.996	.025*	0.923	0.860	0.990
TG/HDL	.00001*	1.357	1.149	1.602	.014*	1.224	1.130	1.315

BMI: body mass index; WC: waist circumference; FBS: fasting blood sugar; TG: triglyceride; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG/HDL: triglyceride/high-density lipoprotein cholesterol; OR: odds ratio; CI: confidence interval.

* Statistically significant at p < .05.

Figure 1. ROC curves of serum TG/HDK ratios for prostate volume cut-off level of (A) 30 ml, (B) 40 ml, and (C) 50 ml.

Figure 2. Correlation test between TG/HDL ratio and prostate volume.